Zobrazeno 1 - 10
of 361
pro vyhledávání: '"Hironori, Koga"'
Autor:
Toru Nakamura, Atsutaka Masuda, Makoto Kako, Hirayuki Enomoto, Masaki Kaibori, Yasuyuki Fujita, Kyoko Tanizawa, Tetsuya Ioji, Yoshihiro Fujimori, Kei Fukami, Takuma Hazama, Hideki Iwamoto, Yasukazu Kako, Kaoru Kobayashi, Hironori Koga, Koji Nagafuji, Takayasu Ohtake, Hiroyuki Suzuki, Tomoyuki Takashima, Toshitaka Tsukiyama, Haruki Uojima, Kenichi Yamahara, Koichiro Yamakado, Hidekazu Yamamoto, Kazunori Yoh, Satoshi Yoshihara, Atsuhiko Kawamoto, Shuhei Nishiguchi, Shuzo Kobayashi, Takuji Torimura, Takumi Kawaguchi
Publikováno v:
Regenerative Therapy, Vol 27, Iss , Pp 455-463 (2024)
Introduction: In this multicenter clinical study, we aimed to investigate the efficacy and safety of the transhepatic arterial administration of granulocyte-colony stimulating factor (G–CSF)–mobilized autologous peripheral blood (PB)-CD34+ cells
Externí odkaz:
https://doaj.org/article/b19699346ecd4bd1940b165cd426aae3
Autor:
Masatoshi Kudo, Kaoru Tsuchiya, Tatsuya Yamashita, Hironori Koga, Yuki Nakagawa, Masafumi Ikeda
Publikováno v:
Liver Cancer (2024)
Externí odkaz:
https://doaj.org/article/df97b2712f874e41b26657e7d8398087
Autor:
Takahiko Sakaue, Hironori Koga, Hideki Iwamoto, Toru Nakamura, Atsutaka Masuda, Toshimitsu Tanaka, Hiroyuki Suzuki, Hideya Suga, Shingo Hirai, Toru Hisaka, Yoshiki Naito, Keisuke Ohta, Kei-ichiro Nakamura, Karuppaiyah Selvendiran, Yoshinobu Okabe, Takuji Torimura, Takumi Kawaguchi
Publikováno v:
Gastro Hep Advances, Vol 3, Iss 6, Pp 761-772 (2024)
Background and Aims: Precise diagnostic biomarkers are urgently required for pancreatic ductal adenocarcinoma (PDAC). Therefore, the aim of this study was to identify PDAC-specific exosomal microRNAs (Ex-miRs) from pancreatic juice (PJ) and evaluate
Externí odkaz:
https://doaj.org/article/0bd6bf97ce7742739998df37a350eb8b
Autor:
Hiroyuki Suzuki, Miwa Sakai, Hideki Iwamoto, Shigeo Shimose, Takashi Niizeki, Masahito Nakano, Tomotake Shirono, Yu Noda, Etsuko Moriyama, Ryoko Kuromatsu, Hironori Koga, Takumi Kawaguchi
Publikováno v:
Gastro Hep Advances, Vol 3, Iss 4, Pp 506-509 (2024)
Externí odkaz:
https://doaj.org/article/bb9aae8499d14e3c8343f934c63beeb9
Autor:
Hideki Iwamoto, Hiroyuki Suzuki, Atsutaka Masuda, Takahiko Sakaue, Toru Nakamura, Toshimitsu Tanaka, Miwa Sakai, Yasuko Imamura, Hirohisa Yano, Takuji Torimura, Hironori Koga, Kaori Yasuda, Masakatsu Tsurusaki, Takahiro Seki, Takumi Kawaguchi
Publikováno v:
iScience, Vol 27, Iss 2, Pp 108797- (2024)
Summary: Current approved anti-angiogenic drugs (AAD) for hepatocellular carcinoma (HCC) inhibit tumor angiogenesis, but affect the hepatic vasculature resulting in adverse effects. Tumor endothelial cells (TECs) differ from normal endothelial cells.
Externí odkaz:
https://doaj.org/article/031aaec1a390453d82be69fc0ff3cd30
Autor:
Shigeo Shimose, Hideki Iwamoto, Tomotake Shirono, Masatoshi Tanaka, Takashi Niizeki, Masahiko Kajiwara, Satoshi Itano, Yoichi Yano, Satoru Matsugaki, Etsuko Moriyama, Yu Noda, Masahito Nakano, Ryoko Kuromatsu, Hironori Koga, Takumi Kawaguchi
Publikováno v:
Cancer Medicine, Vol 12, Iss 11, Pp 12325-12335 (2023)
Abstract Background and Aims We aimed to validate the predictive factors for tumor response and the prognostic impact of conversion therapy aimed at cancer‐ and drug‐free states in patients with unresectable hepatocellular carcinoma (u‐HCC) und
Externí odkaz:
https://doaj.org/article/26571559f9b244bc907903ba1baffeb9
Autor:
Hironori Koga, Hideki Iwamoto, Hiroyuki Suzuki, Shigeo Shimose, Masahito Nakano, Takumi Kawaguchi
Publikováno v:
Clinical and Molecular Hepatology, Vol 29, Iss 2, Pp 242-251 (2023)
Striking advances in systemic therapy for unresectable advanced hepatocellular carcinoma (HCC) have improved the average prognosis of patients with HCC. As a result, the guidelines for the treatment of HCC have changed significantly. However, various
Externí odkaz:
https://doaj.org/article/857fd30faa134a169757cc9f714c6306
Autor:
Hiroyuki Suzuki, Hideki Iwamoto, Takahiro Seki, Toru Nakamura, Atsutaka Masuda, Takahiko Sakaue, Toshimitsu Tanaka, Yasuko Imamura, Takashi Niizeki, Masahito Nakano, Shigeo Shimose, Tomotake Shirono, Yu Noda, Naoki Kamachi, Miwa Sakai, Kazutoyo Morita, Masamichi Nakayama, Tomoharu Yoshizumi, Ryoko Kuromatsu, Hirohisa Yano, Yihai Cao, Hironori Koga, Takuji Torimura
Publikováno v:
Cancer Communications, Vol 43, Iss 4, Pp 415-434 (2023)
Abstract Background Antiangiogenic tyrosine kinase inhibitors (TKIs) provide one of the few therapeutic options for effective treatment of hepatocellular carcinoma (HCC). However, patients with HCC often develop resistance toward antiangiogenic TKIs,
Externí odkaz:
https://doaj.org/article/b014bbfe6ace4455a5688b7b5212c659
Autor:
Shigeo Shimose, Atsushi Hiraoka, Masatoshi Tanaka, Hideki Iwamoto, Takaaki Tanaka, Kazunori Noguchi, Hajime Aino, Taizo Yamaguchi, Satoshi Itano, Hideya Suga, Takashi Niizeki, Etsuko Moriyama, Tomotake Shirono, Yu Noda, Naoki Kamachi, Shusuke Okamura, Masahito Nakano, Takumi Kawaguchi, Ryoko Kuromatsu, Hironori Koga, Takuji Torimura
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-11 (2022)
Abstract This study aimed to investigate the clinical characteristics of patients with unresectable hepatocellular carcinoma (HCC), who were eligible for sequential systemic therapy. We evaluated 365 patients with HCC who underwent systemic therapy a
Externí odkaz:
https://doaj.org/article/a8c7a028541d4aafa780bbde3d8cc0b9
Autor:
Tomotake Shirono, Hideki Iwamoto, Takashi Niizeki, Shigeo Shimose, Akira Kajiwara, Hiroyuki Suzuki, Naoki Kamachi, Yu Noda, Shusuke Okamura, Masahito Nakano, Ryoko Kuromatsu, Kenta Murotani, Hironori Koga, Takuji Torimura
Publikováno v:
Hepatology Communications, Vol 6, Iss 9, Pp 2594-2604 (2022)
Abstract In 2013 and 2014, the development of microcatheters with balloons for the 4‐Fr system and new embolization materials provided various options for transarterial chemoembolization (TACE), expanding the range of treatment strategies. At our h
Externí odkaz:
https://doaj.org/article/cb0c660a9fca4c04b06ac51b42f33a78